Celcuity Inc. Announces Plan to Initiate a Phase 3 Clinical Trial for Gedatolisib as First-Line Treatment for HR+/HER2- Advanced Breast Cancer and Secures Approximately $62 Million Debt Financing
30 mai 2024 07h00 HE
|
Celcuity Inc.
The Phase 3 clinical trial will evaluate gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast cancer who are endocrine therapy...
TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138
29 mai 2024 09h15 HE
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138
GTG Launches Revolutionary geneType Test covering 100% Risk of Breast and Ovarian Cancer
29 mai 2024 08h00 HE
|
Genetic Technologies Ltd
Genetic Technologies Launches Revolutionary geneType Test covering 100% Risk of Breast and Ovarian Cancer
Tokio Marine HCC – Specialty Group and Susan G. Komen® Pair Up With World No. 1 Golfer Nelly Korda to Help End Breast Cancer
28 mai 2024 08h00 HE
|
Tokio Marine HCC
Campaign Led by Tokio Marine HCC – Specialty Group Aims to Improve and Save Lives Impacted by Breast Cancer as Susan G. Komen Works to Provide Access to High-Quality Breast Care and Services. ...
Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)
28 mai 2024 06h30 HE
|
G1 Therapeutics
Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 ADC
Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress
23 mai 2024 17h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., May 23, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two abstracts, including one for ARV-766 in prostate cancer and one for TACTIVE-K, a Phase 1b/2...
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)
16 mai 2024 06h00 HE
|
Arvinas Inc.
– After six months of additional follow-up, clinical benefit rate (63%), overall response rate (41.9%), median progression-free survival (11.2 months), and safety profile of vepdegestrant in...
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
09 mai 2024 16h42 HE
|
Arvinas Inc.
NEW HAVEN, Conn., May 09, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two posters, including updated clinical trial data, for vepdegestrant will be presented at the...
Celcuity Inc. Schedules Release of First Quarter 2024 Financial Results and Webcast/Conference Call
08 mai 2024 07h05 HE
|
Celcuity Inc.
MINNEAPOLIS, May 08, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it...
Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress
08 mai 2024 07h02 HE
|
Olema Oncology
SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...